PRESS RELEASE August 7, 2017

CYTOVIA Inc., IMMUNE Pharma’s Oncology Subsidiary, Announces the Publication of New Results in the British Journal of Haematology and Filing of a World-wide Patent Protecting the Use of Ceplene® in Chronic Myeloid Leukemia (CML)

Strengthens Intellectual property portfolio and expands potential clinical use and market opportunity August 07, 2017 09:27 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Cytovia, the oncology subsidiary of Immune Pharmaceuticals (NASDAQ:IMNP) (“Immune” or the “Company”), a clinical stage biopharmaceutical company, today announced the publication of new results supporting the benefits of its lead compound Ceplene® (histamine […]

Keep Reading

PRESS RELEASE August 4, 2017

Immune Pharmaceuticals, Inc. Issues Letter to Shareholders

August 04, 2017 10:16 AM Eastern Daylight Time ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Immune Pharmaceuticals Inc. (NASDAQ; IMNP) a clinical stage biopharmaceutical company specializing in the development of novel targeted therapeutic agents in the fields of immuno-inflammation, dermatology and immuno-oncology, issued the following Letter to Shareholders. Dear Immune Shareholder, Set out below are a review of our asset […]

Keep Reading

PRESS RELEASE July 19, 2017

Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company

Immune shareholders to receive additional pro rata shares in Cytovia July 19, 2017 09:32 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Immune Pharmaceuticals (NASDAQ: IMNP) (“Immune”) today confirmed it is continuing to structure and pursue a spin-off of Cytovia, Inc. (“Cytovia”), its subsidiary dedicated to the development and commercialization of Oncology drugs and drug candidates, into […]

Keep Reading

PRESS RELEASE July 13, 2017

IMMUNE Pharmaceuticals’ Oncology Subsidiary, CYTOVIA, Announces the Filing of a World-Wide Patent Protecting the Use of Ceplene® in Acute Myeloid Leukemia (AML) and Other Hematological Cancers with Mutated NPM1

Favorable relapse-free and overall survival in AML patients with persistent leukemic cells July 13, 2017 07:30 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Cytovia, Inc. (“Cytovia”) the oncology subsidiary of Immune Pharmaceuticals Inc. (NASDAQ:IMNP) (“Immune” or the “Company”), a clinical stage biopharmaceutical company, announced the filing of a patent protecting the use of Ceplene® (histamine dihydrochloride) […]

Keep Reading

PRESS RELEASE July 11, 2017

Cytovia Inc, Immune Pharmaceuticals’ Oncology Subsidiary, Enters into a Definitive Agreement with Pint Pharma for the Licensing and Commercialization of Ceplene® in Latin America

NEW YORK–(BUSINESS WIRE)–Cytovia Inc. (“Cytovia”) the oncology subsidiary of Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune”) announced today that it has entered into a licensing agreement with Pint Pharma International S.A. (“Pint”) a pharmaceutical company focused on Latin America and other markets, for the marketing and distribution of Ceplene throughout Latin America (the “territory”). Pint Gmbh will separately enter into […]

Keep Reading